Temozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal Cancer
Colon | Rectum
What is the purpose of this trial?
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
- Trial withYale University
- Start Date02/17/2020
- End Date01/30/2022
- Last Updated05/28/2020
- Study HIC#2000026632